237 related articles for article (PubMed ID: 27619249)
1. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
[TBL] [Abstract][Full Text] [Related]
2. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development.
Ansher SS; Scharf R;
Ann N Y Acad Sci; 2001 Dec; 949():333-40. PubMed ID: 11795372
[TBL] [Abstract][Full Text] [Related]
4. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
5. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
7. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
8. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
11. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
12. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
14. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
[TBL] [Abstract][Full Text] [Related]
15. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
16. Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
Smith M; Ho PT
Invest New Drugs; 1996; 14(1):11-22. PubMed ID: 8880389
[TBL] [Abstract][Full Text] [Related]
17. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
[TBL] [Abstract][Full Text] [Related]
18. Gd-Tex Pharmacyclics Inc.
Radford IR
Curr Opin Investig Drugs; 2000 Dec; 1(4):524-8. PubMed ID: 11249709
[TBL] [Abstract][Full Text] [Related]
19. Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience.
Ree AH; Hollywood D
Radiother Oncol; 2013 Jul; 108(1):3-16. PubMed ID: 23830196
[TBL] [Abstract][Full Text] [Related]
20. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]